实体肿瘤治疗相关性白血病2例报告

Two Case Reports of Solid Tumor Treatment-Related Leukemia

实体瘤治疗后继发白血病也称治疗相关性白血病(treatment-related leukemia),随着对于癌症患者治疗关注度提高,化疗药物的剂量、种类以及联合用药都在不断变化。癌症患者的生存率也有所提高。随之TRL群体也在逐渐增多。我院自2018年至2019年相继发现2例确诊实体瘤继发白血病患者,由于不同原因未能进行免疫表型分析及遗传学等相关检查,但根据患者病例资料及外周血细胞数量和形态学分析初步诊断为TRL。

The secondary leukemia after the solid tumor treatment is also called the treatment-related leukemia(TRL).With the increase of the concern about the treatment on cancer patients,the doses,types,and drug combinations for chemotherapeutic agents are constantly changing.From 2018 to 2019,2 patients with secondary leukemia after solid tumor were identified in our hospital.For different reasons,these two patients failed to carry out immunophenotype analysis and genetic examination.But they were initially diagnosed as TRL according to patient′s case data,peripheral blood cell number and morphological analysis.The report is summarized as follows.